Search results for "immunogenic"

showing 10 items of 173 documents

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.

2005

Abstract German adolescents ( n  = 123) without previous pertussis vaccination, no history of pertussis and low IgG-anti-pertussis-toxin (PT) levels received one dose of the Tdap vaccine Boostrix™. Blood samples were taken before, and 5–12 days and 29–49 days after vaccination. IgG- and IgA-anti-PT, IgG- and IgA-anti filamentous hemagglutinin, IgG-anti-pertactin, IgG-anti-tetanus-toxin, and IgG-anti-diphtheria-toxin were measured by ELISA. 88.6% of subjects had an immune response to PT, and all vaccinees had an immune response to at least one pertussis antigen 29–49 days after vaccination. IgA-anti-PT and IgA-anti-FHA responses were found in 43 and 81% of subjects, respectively. This study …

MaleAdolescentWhooping CoughFilamentous haemagglutinin adhesinDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisImmune systemAntigenImmunitymedicineHumansWhooping coughImmunization ScheduleAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthmedicine.diseaseVirologyAntibodies BacterialVaccinationInfectious DiseasesImmunoglobulin GImmunologyMolecular MedicineFemalebusinessAcellular pertussisVaccine
researchProduct

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection …

2021

Clinical and biological assessment of the COVID-19 vaccine efficacy in the frail population is of crucial importance. The study focuses on measuring the levels of anti-SARS-CoV-2 IgG antibodies before and after BNT162b2 mRNA COVID-19 vaccination among long-term care facility (LTCF) elderly residents. We conducted a prospective, single-center, observational study among LTCF residents. The study protocol was based on three blood sample acquisitions: first taken at baseline—5 days before the first dose of the vaccine, second—20 days after the first dose, and third—12 days after the second shot of the vaccine. The comparison was made for two cohorts: patients with and without prior COVID-19 inf…

MaleAgingFrailtySARS-CoV-2COVID-19COVID-19 vaccinesLong-term careImmunogenicity VaccineOlder adultsHumansFemaleProspective StudiesRNA MessengerGeriatrics and GerontologyGerontologyBNT162 VaccineResearch ArticleAgedBiogerontology
researchProduct

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

2021

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolle…

MaleCancer ResearchTime Factors2435immunogenicity0302 clinical medicineRisk FactorsNeoplasmsvaccineClinical endpointImmunology and Allergyantibodiesantibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine1506Prospective Studies030212 general & internal medicineImmune Checkpoint InhibitorsRC254-282Clinical/Translational Cancer ImmunotherapyAged 80 and overIncidenceIncidence (epidemiology)virus diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedVaccinationTreatment OutcomeItalyOncologyInfluenza Vaccines030220 oncology & carcinogenesisMolecular MedicineFemaleimmunotherapyAdultmedicine.medical_specialtyInfluenza vaccineImmunologyVaccine EfficacyimmunizationRisk AssessmentYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineHumansLung cancerAdverse effectAgedPharmacologybusiness.industryCancermedicine.diseasevaccinationImmunizationbusinessneoplasm
researchProduct

Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Childr…

2001

Objectives.To determine the reactogenicity and immunogenicity of a fourth dose of 2 three-component acellular pertussis vaccines combined with diphtheria-tetanus-acellular pertussis (DTaP) when administered at preschool age to children primed in infancy with 3 doses of the same DTaP and who had received a diphtheria-tetanus (DT) dose at the age of 12 months.Setting.Local health units of 4 Italian regions.Study Design.Three thousand five hundred twenty-two children, who had been randomized in the first year of life to be immunized with a DTaP vaccine by either SmithKline Beecham or Chiron Biocine, were offered a booster of the same vaccine or, if refusing, a DT vaccine at the age of 5 to 6 y…

MaleDiphtheria-Tetanus VaccinePediatricsmedicine.medical_specialtyImmunization SecondaryBooster doseInjectionsmedicineHumansProspective StudiesChildAdverse effectDiphtheria-Tetanus-Pertussis VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesBooster (rocketry)Reactogenicitybusiness.industryImmunogenicityItalyChild PreschoolPediatrics Perinatology and Child HealthPertussis vaccineFemalePertactinbusinessmedicine.drugPediatrics
researchProduct

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vacc…

2003

Safety, reactogenicity and immunogenicity of GSK Biologicals` hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix(R)hexa) was assessed when used for primary vaccination at 3, 4 and 5 months of age (N = 2163), compared to the separate administration of DTPa-IPV/Hib and HBV vaccines (N = 720). A similar safety and reactogenicity profile was demonstrated for both vaccine regimens, as well as a good immune response for all antigen components. By offering protection against six diseases in it series of single injections, the hexavalent DTPa-HBV-IPV/Hib vaccine was shown to be a safe, well tolerated and immunogenic alternative to primary immunization with licensed separately administered vaccines. (C) …

MaleHaemophilus InfectionsDiphtheria ToxoidWhooping Coughmedicine.disease_causecomplex mixturesHaemophilus influenzaeConjugate vaccinemedicineTetanus ToxoidHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPertussis VaccineReactogenicityTetanusGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationPublic Health Environmental and Occupational HealthInfantDiphtheriamedicine.diseaseHepatitis BVirologyPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyInactivated Poliovirus VaccineMolecular MedicineFemalebusinessPoliomyelitisVaccine
researchProduct

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spa…

2013

Abstract Background Given the concurrent administration of multiple vaccines during routine pediatric immunizations, efforts to elucidate the potential interference of any vaccine on the immune response to the concomitantly administered antigens are fundamental to prelicensure clinical research. Methods This phase 3 randomized controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) versus 7-valent PCV (PCV7) assessed immune responses of concomitantly administered meningococcal group C conjugated to diphtheria toxin cross-reactive material 197 (MnCCV-CRM 197 ) in a 2-dose infant series and 15-month toddler dose. Results 619 subjects were randomized, 315 to PCV13 and 304 to PCV7.…

MaleHeptavalent Pneumococcal Conjugate VaccineMeasles-Mumps-Rubella VaccineDrug-Related Side Effects and Adverse ReactionsMeningococcal VaccinesPneumococcal conjugate vaccinePneumococcal VaccinesConjugate vaccineMedicineHumansToddlerImmunization ScheduleGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityVaccinationPublic Health Environmental and Occupational HealthAntibody titerInfantAntibodies BacterialHealthy VolunteersTiterInfectious DiseasesTolerabilitySpainImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response

2019

The development of a vaccine against human cytomegalovirus infection (HCMV) is a high-priority medical goal. The viral pentameric protein complex consisting of glycoprotein H (gH)/gL/UL128-131A (PC) is considered to be an important vaccine component. Its relevance to the induction of a protective antibody response is, however, still a matter of debate. We addressed this issue by using subviral dense bodies (DBs) of HCMV. DBs are exceptionally immunogenic. Laboratory HCMV strain DBs harbor important neutralizing antibody targets, like the glycoproteins B, H, L, M, and N, but they are devoid of the PC. To be able to directly compare the impact of the PC on the levels of neutralizing antibody …

MaleHuman cytomegalovirusForeskinImmunologyCongenital cytomegalovirus infectionCytomegalovirusMutagenesis (molecular biology technique)MicrobiologyVirusCytomegalovirus VaccinesMiceViral Envelope ProteinsAntigenVirologyVaccines and Antiviral AgentsHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansNeutralizing antibodyCells Culturedchemistry.chemical_classificationMembrane GlycoproteinsbiologyImmunogenicitymedicine.diseaseAntibodies NeutralizingVirologychemistryMultiprotein ComplexesInsect ScienceCytomegalovirus Infectionsbiology.proteinRabbitsGlycoproteinJournal of Virology
researchProduct

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infant…

2007

The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC …

MaleImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineMeningitis Meningococcalmedicine.disease_causeMeningococcal diseaseConjugate vaccinemedicineHumansHepatitis B VaccinesVaccines CombinedHepatitis B AntibodiesBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHepatitis B virusReactogenicityMicrobial ViabilityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunologyMolecular MedicineFemalebusinessImmunologic MemoryVaccine
researchProduct

Oncogene transformation can induce tolerogenicity in murine macrophages after down-regulation of immunogenicity without altering major histocompatibi…

1993

In vitro studies on cell lines may allow analyses of the mechanisms of immunogenicity and tolerogenicity in cells. We used a model of oncogenic transformation of an established murine macrophage cell line and report here that one v-mos-transformed clone expressing unaltered high amounts of MHC class I and II antigens does not induce proliferation of unprimed T cells in primary mixed lymphocyte reactions, in sharp contrast to its non-transformed parental cells. Interestingly, this clone induces specific unresponsiveness, as revealed by the lack of responsiveness of MHC-specific T cells when subsequently exposed to the pertinent MHC alloantigens in immunogenic form but unaltered MHC-third par…

MaleLymphocyteT-LymphocytesImmunologyClone (cell biology)Down-RegulationBiologyMajor histocompatibility complexImmune toleranceCell LineMiceTransformation GeneticAntigenHistocompatibility AntigensMHC class ImedicineImmune ToleranceAnimalsRNA MessengerGenes mosMice Inbred BALB CMice Inbred C3HImmunogenicityMacrophagesGeneral MedicineCell biologyClone CellsMice Inbred C57BLmedicine.anatomical_structureCell cultureImmunologybiology.proteinFemaleLymphocyte Culture Test MixedCell DivisionInterleukin-1Scandinavian journal of immunology
researchProduct

Significant in vivo anti-inflammatory activity of Pytren4Q-Mn a superoxide dismutase 2 (SOD2) mimetic scorpiand-like Mn (II) complex.

2015

Background The clinical use of purified SOD enzymes has strong limitations due to their large molecular size, high production cost and immunogenicity. These limitations could be compensated by using instead synthetic SOD mimetic compounds of low molecular weight. Background/Methodology We have recently reported that two SOD mimetic compounds, the MnII complexes of the polyamines Pytren2Q and Pytren4Q, displayed high antioxidant activity in bacteria and yeast. Since frequently molecules with antioxidant properties or free-radical scavengers also have anti-inflammatory properties we have assessed the anti-inflammatory potential of Pytren2Q and Pytren4Q MnII complexes, in cultured macrophages …

MaleMAP Kinase Signaling Systemmedicine.drug_classAnti-Inflammatory AgentsSOD2lcsh:MedicineBiologymedicine.disease_causeAnti-inflammatoryCell LineSuperoxide dismutaseMicechemistry.chemical_compoundIn vivoChlorocebus aethiopsmedicineAnimalsHumanslcsh:ScienceVero Cellschemistry.chemical_classificationManganeseMultidisciplinarySuperoxide DismutaseSuperoxideImmunogenicityMolecular Mimicrylcsh:RMolecular mimicryEnzymechemistryBiochemistrybiology.proteinlcsh:QResearch ArticlePLoS ONE
researchProduct